DOI QR코드

DOI QR Code

Clinical Significance of Quantitative Analysis of Plasma Epstein-Barr Virus DNA in Patients of Xinjiang Uygur Nationality with Hodgkin's Lymphoma

  • Li, Xun (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Yang, Shun-E. (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Guo, Yun-Quan (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Shen, Ming-Xia (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Gu, Li (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Gulikezi, Gulikezi (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Zhao, Bing (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Liu, Wei (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Tuerxun, Tuerxun (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University) ;
  • Bai, Jing-Ping (Department of Medical Oncology, Affiliated Tumor Hospital, Xinjiang Medical University)
  • Published : 2012.12.31

Abstract

Objective: To investigate the relationship between plasma EBV-DNA concentration and clinicopathologic features of Hodgkin's lymphoma cases. Methods: At first, the positive rate of plasma EBV-DNA was determined with a nested-PCR method using 45 specimens from Uygur HL patients, as well as 110 healthy people sampled as normal controls. Secondly, using fluorescent quantitative nested-PCR, EBV viral load was assessed in the EBV-DNA positive plasma samples. Then, relationships between plasma EBV viral load and clinicopathologic features of HL patients were analyzed. Results: The positive rate of plasma EBV-DNA of HL patients was significantly higher than that of normal controls (53.3% vs 26.4%, P=0.001). There was no significant difference about plasma EBV viral load between EBV-associated HL and EBV-DNA positive normal people (P=0.490). Looking at patients' characteristics, plasma EBV viral load in 10-20 years EBV-associated HL was higher than in EBV cases which were less than 10 years or more than 35 years (P=0.025). Furthermore, in EBV-associated HL, concentration of plasma EBV-DNA was significantly higher in advanced stage disease (stages III-IV; P=0.013), and with B-symptoms (P=0.020). Conclusion: EBV-DNA levels were associated with part of clinicopathologic features of cases. It was of practical use to screen HL. Further etiological studies appear warranted.

Keywords

Hodgkin's lymphoma;Uygur nationality;nested-PCR;Epstein-Barr virus p1asma viral load

References

  1. Massini G, Siemer D, Hohaus S (2009). EBV in hodgkin lymphoma. Mediterr J Hematol Infect Dis, 1, e2009013.
  2. Musacchio JG, Carvelho Mda G, Morais JC, et al (2006). Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin's disease. Sao Paulo Med J, 124, 154-7.
  3. Pajand O, Pourakbari B, Mahjob F, et al (2011). Detection of Epstein-Barr virus DNA in plasma and lymph node biopsy samples of pediatric and adult patients with Hodgkin lymphoma. Pediatr Hematol Oncol, 28, 10-5. https://doi.org/10.3109/08880018.2010.507691
  4. Spacek M, Hubacek P, Markova J, et al (2011). Plasma EBVDNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS, 119, 10-6.
  5. Umetani N, Hiramatsu S, Hoon DS (2006). Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci, 1075, 299-307. https://doi.org/10.1196/annals.1368.040
  6. Wagner HJ, Schlager F, Claviez A, Bucsky P (2001). Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. Eur J Cancer, 37, 1853-7. https://doi.org/10.1016/S0959-8049(01)00152-6
  7. Wagner HJ, Wessel M, Jabs W, et al (2001). Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation, 72, 1012-9. https://doi.org/10.1097/00007890-200109270-00006
  8. Zhou XG, Sandvej K, Li PJ, et al (2001). Epstein-Barr virus (EBV) in Chinese pediatric Hodgkin disease: Hodgkin disease in young children is an EBV-related lymphoma. Cancer, 92, 1621-31. https://doi.org/10.1002/1097-0142(20010915)92:6<1621::AID-CNCR1488>3.0.CO;2-P
  9. Anker P, Mulcahy H, Chen XQ, Stroun M (1999). Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev, 18, 65-73. https://doi.org/10.1023/A:1006260319913
  10. Chabay PA, Barros MH, Hassan R, et al (2008). Pediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol, 30, 285-91. https://doi.org/10.1097/MPH.0b013e3181647bc3
  11. Chan A, Zhung J, Chan A, et al (2003). Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res, 63, 2028-32.
  12. Dinand V, Arya LS (2006). Epidemiology of childhood hodgkins disease: is it different in developing countries? Indian Pediatr, 43, 141-7.
  13. Gallagher A, Armstrong AA, MacKenzie J, et al (1999). Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer, 84, 442-8. https://doi.org/10.1002/(SICI)1097-0215(19990820)84:4<442::AID-IJC20>3.0.CO;2-J
  14. Gandhi MK, Lambley E, Burrows J, et al (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res, 12, 460-4. https://doi.org/10.1158/1078-0432.CCR-05-2008
  15. Halliday C, Wu QX, James G, Sorrell T (2005).Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. J Clin Microbiol, 43, 5366-8. https://doi.org/10.1128/JCM.43.10.5366-5368.2005
  16. Hohaus S, Santangelo R, Giachelia M, et al (2011). The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res, 17, 2885-92. https://doi.org/10.1158/1078-0432.CCR-10-3327
  17. Huang X, Hepkema B, Nolte I, et al (2012). HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLoS One, 7, e31865. https://doi.org/10.1371/journal.pone.0031865
  18. Huang X, Nolte I, Gao Z, et al (2011). Epidemiology of classical hodgkin lymphoma and its association with epstein barr virus in northern China. PLoS One, 6, e21152. https://doi.org/10.1371/journal.pone.0021152
  19. Ishii H, Ogino T, Berger C, et al (2007). Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma. J Med Virol, 79, 562-72. https://doi.org/10.1002/jmv.20853
  20. Jarrett RF (2003). Risk factors for Hodgkin's lymphoma by EBV status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk Lymphoma, 44, S27-32. https://doi.org/10.1080/10428190310001623801
  21. Le QT, Jones CD, Yau TK, et al (2005). A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res, 11, 5700-7. https://doi.org/10.1158/1078-0432.CCR-05-0648
  22. Lo YM, Chan LY, Lo KW, et al (1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59, 1188-91.

Cited by

  1. Type Distribution of Lymphomas in Lebanon: Five-Year Single Institution Experience vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5825
  2. Frequency and Pattern of Bone Marrow Infiltration in Classical Hodgkin's Lymphoma: Experience from Southern Pakistan vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1857